SSX2 and acute myeloid leukemia: Besides WT1, other intracellular antigen peptide-HLA complexes for CAR-T cell therapy have been investigated, including NY-ESO-1/HLA-A2 for potentially MM (18), HA-1H (derived from minor histocompatibility antigen 1, HMHA1)/HLA-A2 for chronic myelogenous leukemia (19), and SSX2/HLA∗0201 for acute myeloid leukemia (AML) (20).